We discuss the use of urine electrolytes and urine osmolality (UOsm) in the clinical diagnosis of some disorders of fluid, electrolytes, and acid-base balance.1–3 Whereas there are usual ranges for the rates of excretion of water and electrolytes and the UOsm, there are no “normal” values. Data should be interpreted in the context of the expected renal response for the clinical situation. For example, a rate of potassium (K⁺) excretion of 60 mmol/d is within the usual range for K⁺ excretion in adults but indicates renal K⁺ wasting in a patient with hypokalemia and a defect in renal K⁺ excretion in a patient with hyperkalemia.

Patients With Potassium Disorders
In response to a low dietary K⁺ intake, the rate of K⁺ excretion in normal individuals fell to 10 to 15 mmol/d.4,5 The rate of K⁺ excretion rose to match K⁺ intake in normal individuals given a large K⁺ load (>200 mmol/d) on a long-term basis, with only a modest rise in the plasma K⁺ concentration (P_K).5,6,9

The urine tests that have been commonly used to assess the renal response to hypokalemia or hyperkalemia are the calculation of the transtubular K⁺ concentration gradient (TTKG) and the ratio of the concentration of K⁺ and the concentration of creatinine in a spot urine sample (U_K/U_Creatinine).

The TTKG
The TTKG was proposed as a semiquantitative index of the driving force for K⁺ secretion in the aldosterone-sensitive distal nephron (ASDN), which includes the second part of the distal convoluted tubule, the connecting segment, and the cortical collecting duct (CCD).8,9 The TTKG is the ratio of the K⁺ concentration in the luminal fluid at the end of the CCD (K_CCD), and the P_K. To estimate K_CCD, U_K is adjusted for water reabsorption in the medullary collecting duct (MCD), by dividing U_K by the ratio of U_Osm to plasma osmolality (P_Osm), because the osmolality of the fluid at the end of the CCD should be equal to P_Osm when arginine vasopressin (AVP) acts.

The assumption in this calculation is that there is no appreciable reabsorption of osmoles in the MCD. Although this is largely correct for electrolytes, it is not for urea because of the process of intrarenal urea recycling.10,11 Extrapolating from micropuncture studies in rats, we estimate that in adult individuals consuming a typical Western diet, ~600 mmol of urea per day is reabsorbed in the inner MCD and recycled back to the distal convoluted tubule.12,13 This adds 2 l/d to the volume of fluid at the end of the CCD (600 osm divided by an osmolality of 300 mosm/kg water [H₂O]), which constitutes ~40% of this volume (~5 l/d).13 Not accounting for urea recycling considerably overestimates K_CCD, because it considerably underestimates the flow rate in the terminal
PDF text
with hypokalemia due to laxative abuse, however, commonly have no significant metabolic acid-base disorder or only a small increase in plasma bicarbonate (HCO₃⁻) concentration.⁹⁷

In patients with chronic hypokalemia, the first step is to examine the acid-base status in plasma.²³,²⁸–³² Patients with metabolic acidosis commonly have HCMA (Figure 1). Notwithstanding, although the hypokalemia in patients with diarrhea is largely due to the loss of K⁺ in diarrhea fluid, the Uₖ/UₖCreatinine may be high if renal excretion of K⁺ is stimulated because of aldosterone released in response to low effective arterial blood volume (EABV), associated magnesium depletion and the effect of acidemia to decrease the reabsorption of Na⁺ and Cl⁻ in the proximal convoluted tubule (PCT). The increased delivery of Na⁺ and Cl⁻ to the ASDN may result in a higher rate of K⁺ excretion because of increased rate of electrogenic reabsorption of Na⁺ and increased flow rate in the ASDN.³³,³⁴

In patients with chronic hypokalemia and metabolic alkalosis, Uₖ/UₖCreatinine < 2 mmol K⁴⁺/mmol creatinine suggests extrarenal K⁺ loss; for example, in sweat (patients with cystic fibrosis) or via the intestinal tract (patients with congenital or acquired chloride wasting diarrhea due to decreased activity of the colonic downregulated in adenoma anion exchanger). Hypokalemia in patients with vomiting is largely due to renal loss of K⁺ because of stimulation of K⁺ secretion in the ASDN by increased delivery of sodium bicarbonate (NaHCO₃)³⁵–³⁷. the Uₖ/UₖCreatinine may be low in these patients in the absence of increased distal delivery of NaHCO₃.

Patients with metabolic alkalosis and Uₖ/UₖCreatinine higher than stated above have renal K⁺ loss. The primary pathophysiology is an increased number of open epithelial Na channels in the luminal membrane of the principal cells in the ASDN leading to a higher rate of electrogenic Na⁺ reabsorption.²⁵,³⁸ This could be due to two groups of disorders. Patients in the first group have low EABV causing the release of aldosterone. Patients in the second group have conditions associated with a primary high mineralocorticoid effect.

The use of chloride concentration in the urine (UₐCl) in the differential diagnosis in patients in the first group is shown in Figure 1. The diuretic effect in some patients may be due to an inherited disorder affecting NaCl reabsorption in the medullary thick ascending limb of the loop of Henle [i.e., Bartter syndrome] or the distal convoluted tubule [i.e., Gitelman syndrome].³⁹,⁴⁰ A clinical picture that mimics Bartter syndrome may result from activation of the calcium-sensing receptor in the medullary thick ascending limb of the loop of Henle by calcium in patients with hypocalcemia or by other cationic ligands (e.g., gentamicin, amikacin, cisplatin, and possibly cationic immunoglobulins).⁴¹–⁴⁴

Acquired Gitelman syndrome has been reported in some patients with autoimmune diseases.⁴⁴–⁴⁶

Measurement of UₐCl in multiple urine samples may help in differentiating patients with Bartter syndrome or Gitelman syndrome (persistently high UₐCl) from those with diuretic abuse (intermittently high UₐCl). An assay for diuretics in the urine, if required, should be performed in urine samples with high UₐCl. Hypocalciuria (UₐCalcium/UₐCreatinine < 0.2 mmol/mmol) is usually present in patients with Gitelman syndrome.⁴⁷,⁴⁸

Patients With Hyperkalemia

Hyperkalemia caused by a shift of K⁺ out of cells is usually recognized by its acute onset and the clinical setting (e.g., rhabdomyolysis, tumor lysis syndrome, immediate postoperative period, diabetic ketoacidosis, hypoxic lactic acidosis). In a case report of hyperkalemia due to toad venom ingestion (contains bufadienolides, which akin to digitalis, inhibit the Na⁺/K⁺ adenosine 5'-triphosphatase), the Uₖ/UₖCreatinine was 15.9, indicating that hyperkalemia was not due to a defect in renal K⁺ excretion.⁴⁹

The Uₖ/UₖCreatinine is less useful in patients with chronic hyperkalemia. This is because to develop chronic hyperkalemia, there must be defect in the renal K⁺ excretion. Hence, the value of assessing K⁺ excretion rate in these patients is to determine whether a large dietary K⁺ intake is contributing to the degree of hyperkalemia. Because of the diurnal variation in K⁺ excretion, this requires a 24-hour urine collection.

A subgroup of patients with chronic hyperkalemia have disorders that cause a decreased number of open epithelial Na channels in the ASDN, leading to decreased rate of electrogenic Na⁺ reabsorption. This includes patients with primary hypoaldosteronism (e.g., Addison disease), patients with pseudohypoaldosteronism type I (e.g., due to molecular defects involving the aldosterone receptor or the epithelial Na channel), and a small subset of patients with hyporeninemic hypoaldosteronism who may have damage to the juxtaglomerular apparatus or a defect in converting prorenin to active renin.⁵⁰ Patients with these disorders tend to have renal salt wasting, low EABV, and inappropriately high Uₙa and UₐCl. Of note, most patients with hyporeninemic hypoaldosteronism, who may also have hyperkalemia, have a clinical picture that mimics the syndrome of hypertension with hyperkalemia (Gordon syndrome or pseudohypoaldosteronism type II).⁵¹ The EABV is not low in these patients, and they do not have renal salt wasting.

PATIENTS WITH POLYURIA

Polyuria is commonly defined by a urine volume that is >3 l/d in adults.
In patients suspected of having polyuria, a 24-hour urine collection should be obtained to measure urine volume, UOsm, creatinine, Na⁺, K⁺, Cl⁻, urea, and glucose and calculate the rate of excretion of osmoles. An UOsm < 250 mosm/kg H₂O suggests a water diuresis. This could be due to diabetes insipidus (DI) or primary polydipsia. The cause of the water diuresis can be determined by examining the change in UOsm in response to a rise in plasma sodium concentration (PNa) to >145 mmol/l and the administration of 1-desamino-8-D-arginine vasopressin (dDAVP). An UOsm > 300 mosm/kg H₂O suggests that the polyuria is due to an osmotic diuresis or a medullary interstitial disease impairing the process of concentrating the urine in the renal medulla. These 2 disorders can be separated by calculating the rate of excretion of osmoles. The cause of the osmotic diuresis can be determined by measuring the individual osmoles in the urine (e.g., glucose, urea, and sodium chloride [NaCl]). A large amount of mannitol is not commonly given; hence, it is not likely to be the sole cause of a large and sustained osmotic diuresis. ATN, acute tubular necrosis; ECFV, extracellular fluid volume.

Polyuria Due to a Water Diuresis

A water diuresis could be due to primary polydipsia or diabetes insipidus (DI). DI may be caused by:

(i) Central DI: due to lesions affecting the neurohypophysis resulting in deficient synthesis and/or release of AVP. A subset of these patients retain the ability to release AVP in the presence of a higher P_Na, hence described as partial central DI.

(ii) Nephrogenic DI: due to lesions that interfere with the binding of AVP to its V2 receptor (AVPR2), its effect is to cause trafficking and insertion of aquaporin water channel 2 (AQP2) in the luminal membrane of principal cells or a defect involving AQP2. Nephrogenic DI may be congenital due to mutations involving the genes encoding for AVPR2 or AQP2 or acquired (most commonly due to intake of lithium).

We prefer not to include patients with a medullary concentrating defect due to a medullary interstitial disease under the category of nephrogenic DI, but rather to characterize them as a separate group. This is because the pathophysiology of the polyuria in these patients is different, their UOsm is usually > 300 mosm/kg H₂O (because UOsm should be at least equal to the osmolality at the end of the CCD, i.e., ~ P_Osm), and from a management perspective, decreasing intake of osmoles is more likely to result in a lower urine volume in this group of patients.

(iii) The presence of a circulating vasopressinase that breaks down AVP. This is commonly caused by its excess release from a large placenta (usually twin or multiple pregnancies) or its impaired degradation by the liver in patients with preeclampsia/HELLP (Hemolysis, Elevated Liver Enzymes, Lowered Platelets) syndrome.

Figure 2. Urine data in the clinical diagnosis of patients with polyuria. The first step is to determine whether the basis of polyuria is a water diuresis or an osmotic diuresis. A urine osmolality (U_Osm) < 250 mosm/kg H₂O suggests a water diuresis. This could be due to diabetes insipidus (DI) or primary polydipsia. The cause of the water diuresis can be determined by examining the change in U_Osm in response to a rise in plasma sodium concentration (PNa) to >145 mmol/l and the administration of 1-desamino-8-D-arginine vasopressin (dDAVP). A U_Osm > 300 mosm/kg H₂O suggests that the polyuria is due to an osmotic diuresis or a medullary interstitial disease impairing the process of concentrating the urine in the renal medulla. These 2 disorders can be separated by calculating the rate of excretion of osmoles. The cause of the osmotic diuresis can be determined by measuring the individual osmoles in the urine (e.g., glucose, urea, and sodium chloride [NaCl]). A large amount of mannitol is not commonly given; hence, it is not likely to be the sole cause of a large and sustained osmotic diuresis. ATN, acute tubular necrosis; ECFV, extracellular fluid volume.
Because of difficulties with the measurement of AVP due to its instability in drawn blood samples and inaccuracy of commercially available assays, and because measurements of copeptin are not widely available, clinicians rely on measurement of the change in $U_{\text{osm}}$ in response to a sufficient osmotic stimulus (a rise in $P_{\text{Na}}$ to >145 mmol/L with water deprivation) and after the administration of 1-desamino-8-d-arginine vasopressin (DDAVP) to determine the cause of a water diuresis.

Chronic polyuria decreases the ability to concentrate the urine because of medullary washout. A larger volume of water is reabsorbed in the MCD during water diuresis than during antidiuresis. The resultant increase in flow in the ascending vasa recta impairs the efficiency of the countercurrent exchange between the ascending and the descending vasa recta and the surrounding medullary interstitium. Therefore, if there is a renal response to the release of AVP or the administration of DDAVP, the rise in $U_{\text{osm}}$ may vary depending on the degree of this medullary washout but is expected to be at least to a value exceeding the osmolality at the end of the CCD ($\sim P_{\text{osm}}$).

A rise in $U_{\text{osm}}$ to a value that is $>P_{\text{osm}}$ in response to a rise in $P_{\text{Na}}$ >145 mmol/L suggests that the cause of the water diuresis is primary polydipsia or partial central DI.

DDAVP is administered if this response to a rise in $P_{\text{Na}}$ >145 mmol/L is not observed. A rise in $U_{\text{osm}}$ to $>P_{\text{osm}}$ in response to the administration of DDAVP suggests that the cause of the water diuresis is complete central DI. Notwithstanding, although the $U_{\text{osm}}$ of 3 of the 7 patients who were thought to have central DI in the study by Zerbe and Robertson more than doubled after the administration of AVP, it did not rise to a value $>P_{\text{osm}}$. This could be interpreted to suggest downregulation of AQP2 during water diuresis. Of note however, $U_{\text{osm}}$ was measured at 30 and 60 minutes after the administration of AVP; hence, mixing of urines with low and higher osmolality (especially if there is incomplete bladder emptying) may be suspected.

A rise in $U_{\text{osm}}$ to a value $>P_{\text{osm}}$ after the administration of DDAVP is also expected in patients with water diuresis caused by breakdown of AVP by a circulating vasopressinase, because DDAVP is not degraded by these enzymes. These patients are expected not to respond to the administration of AVP. This investigation should not be attempted in pregnant women, because AVP has an oxytocic effect, unlike DDAVP which has been safely administered during pregnancy.

If the $U_{\text{osm}}$ fails to rise appropriately in response to a rise in $P_{\text{Na}}$ >145 mmol/L and the administration of DDAVP, the diagnosis is nephrogenic DI (Figure 2).

### Polyuria Due to an Osmotic Diuresis

A $U_{\text{osm}}$ >300 mosmol/kg H_2O suggests that the polyuria is caused by an osmotic diuresis and/or a low medullary interstitial osmolality due to a medullary interstitial disease. These 2 disorders can be differentiated by calculating the rate of excretion of osmoles in a timed urine collection (multiply the urine flow rate by the $U_{\text{osm}}$). The usual rate of excretion of osmoles in adults consuming a typical Western diet is $\sim$0.5 mosmol/min. In patients with osmotic diuresis, the osmole excretion rate is usually >1 mosmol/min. Conversely, if the osmole excretion rate is appreciably less than that, a medullary concentrating defect with a higher than usual rate of excretion of osmoles (e.g., in a patient who consumes a diet high in salt and animal protein) may be suspected.

An osmotic diuresis may be due to organic (mannitol, urea, or glucose) or NaCl osmoles, or a combination of these osmoles (Figure 2).

In patients with urea-induced osmotic diuresis, it is important to determine whether the source of urea is exogenous from the intake of proteins or endogenous from catabolism of tissue proteins. Because close to 16% of the weight of protein is nitrogen, 16 g of nitrogen will be produced when 100 g of protein is oxidized. The molecular mass of nitrogen is 14, and each molecule of urea contain 2 atoms of nitrogen; therefore, $\sim$570 mmol of urea is produced from the oxidation of 100 g of protein.

### Patients With Acute Dysnatremia

Calculations of electrolyte free water (EFW) balance and tonicity balance are used to determine the basis for an acute change in $P_{\text{Na}}$ and the therapy needed to return the $P_{\text{Na}}$ to a normal value. These calculations can only
be done in a hospital setting, where inputs and outputs are recorded and the concentrations of electrolytes in the urine are measured.

The difference between these 2 calculations is illustrated with case examples of 3 patients, in each of whom P_{Na} rose from 140 mmol/l to 147 mmol/l (Table 1). Each patient excreted 3 L of urine with (U_{Na} + U_{K}) of 50 mmol/l, patient 1 received 3 L of isotonic saline (Na\(^+\) concentration 154 mmol/l), patient 2 received 4 L of isotonic saline, and patient 3 received no i.v. fluids. Total body water in each patient was 40 L.

**EFW Balance**

Because urea is not an effective osmole in the body, calculation of EFW balance rather than osmole free water balance was suggested to determine the basis of a dysnatremia and its impact on cell volume.\(^6\) This calculation is based on determining how much water needs to be added to (or subtracted from) a solution to make its tonicity equal to the normal plasma tonicity. In the absence of hyperglycemia, tonicity of plasma water is approximated by the plasma tonicity. In the absence of hyperglycemia, the latter is associated with a fall in pH in proximal convoluted tubule cells and increased production of NH_4\(^+\). The U_{Na} and U_{Cl} may not be high in patients with disorders associated with renal loss of Na\(^+\) and Cl\(^-\), if there is marked degree of decreased effective arterial blood volume as mechanisms to enhance Na\(^+\) and Cl\(^-\) reabsorption in nephron segments other than those affected by the disorder are activated.

### Table 2. Urine Na\(^+\) and urine Cl\(^-\) concentrations in patients with decreased effective arterial blood volume

| Condition                      | Urine Na\(^+\) | Urine Cl\(^-\) |
|--------------------------------|----------------|----------------|
| Vomiting                       |                |                |
| Recent                         | High           | Low            |
| Remote                         | Low            | Low            |
| Diuretics                      |                |                |
| Recent                         | High           | High           |
| Remote                         | Low            | Low            |
| Diarrhea/some patients with laxative abuse | Low | High |
| Bartter syndrome/Gitelman syndrome/Bartter-like syndrome | High | High |
| Cerebral/renal salt wasting    | High           | High           |
| Some patients with hyporeninemic hypoaldosteronism | High | High |
| Adrenal insufficiency          | High           | High           |

\(^6\)High: urine concentration of Na\(^+\) or Cl\(^-\) >15 mmol/l; low: urine concentration of Na\(^+\) or Cl\(^-\) <15 mmol/l. Urine Cl\(^-\) may be high in patients with laxative abuse if they have a high rate of excretion of NH_4\(^+\) because of metabolic acidemia or because of hypokalemia, the latter is associated with a fall in pH in proximal convoluted tubule cells and increased production of NH_4\(^+\). The U_{Na} and U_{Cl} may not be high in patients with disorders associated with renal loss of Na\(^+\) and Cl\(^-\), if there is marked degree of decreased effective arterial blood volume as mechanisms to enhance Na\(^+\) and Cl\(^-\) reabsorption in nephron segments other than those affected by the disorder are activated.

A toxicity balance refers to the balance of both water and of (Na\(^+\) + K\(^+\)).\(^70\) To calculate a toxicity balance, one needs to know the volumes and the quantity of (Na\(^+\) + K\(^+\)) of the input and the urine over the time period the P_{Na} has changed.

Calculation of toxicity balance reveals that while it is true that the basis for the rise in P_{Na} in all 3 patients is a net negative balance of 2 L of EFW, this is the result of rather quite different balances for water and for (Na\(^+\) + K\(^+\)) in each of them (Table 1). Hence, the design of the appropriate therapy to return P_{Na} to its normal value and restore the normal volume and composition of the ECF and ICF compartments is different for each one of them.

### Patients With Low EABV

In response to decreased EABV, mechanisms that lead to retention of Na\(^+\) and Cl\(^-\) by the kidney are activated. Because 24-hour urine collections to measure the excretion rates of Na\(^+\) and Cl\(^-\) are not practical in clinical settings, U_{Na} and U_{Cl} values of <15 mmol/l in spot urine samples are used instead to suggest decreased EABV. These are concentration terms that are also affected by the urine flow rate. The 24-hour excretion rate can be estimated by multiplying the ratio of U_{Na} or U_{Cl}/U_{Creatinine} by an estimate of the 24-hour creatinine excretion based on the patient’s muscle mass.

There are some caveats in using U_{Na} and U_{Cl} to detect low EABV (Table 2).\(^30\) A low rate of excretion of Na\(^+\) and Cl\(^-\) may reflect a low intake of NaCl rather than a low EABV. The U_{Na} might not be low despite low EABV if the excretion of the cation Na\(^+\) is obligated by the excretion of an anion other than Cl\(^-\) (e.g., HCO_3^-) in a patient with recent vomiting [bicarbonaturia is suggested by the finding of an alkaline urine pH], anions of drugs such as piperacillin or carbenicillin). The U_{Cl} may not be low despite low EABV if the excretion of the anion Cl\(^-\) is obligated by the excretion of another cation (e.g., NH_4\(^+\) in patients with diarrhea, lithium in patients with lithium intoxication). Both U_{Na} and U_{Cl} may not be low despite low EABV in patients with diuretic use/abuse, patients with Bartter syndrome or Gitelman syndrome, patients with adrenal insufficiency, patients with cerebral/renal salt wasting, and in a subset of patients with hyporeninemic hypoaldosteronism.
Patients With Hyponatremia

The clinical approach to the patients with hyponatremia centers on determining the cause of the release of AVP despite hypotonicity. In one group of patients, AVP release is due to decreased EABV. In contrast, in the group of patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) or the syndrome of inappropriate antidiuresis to include patients with mutations in AVPR2 causing it to be constitutively active, the release of AVP is not caused by low EABV.\textsuperscript{74,75} Notwithstanding, the degree of decreased EABV in some of the patients who are considered in the first group (e.g., some patients with thiazide-induced hyponatremia, patients with “tea and toast” hyponatremia) does not seem to be large enough to cause the release of AVP.\textsuperscript{76–79} Reduced EFW excretion in these patients may be caused by a decreased volume of filtrate delivered to the distal nephron as a result of increased reabsorption in the PCT in response to a mild degree of EABV contraction, particularly in elderly patients with reduced glomerular filtration rate, and the presence of other mechanisms for water reabsorption in the distal nephron that are independent of AVP actions.\textsuperscript{79–82}

A mild degree of EABV contraction cannot be reliably detected by physical examination.\textsuperscript{83,84} Laboratory tests that are based on the expected renal response to decreased EABV are suggested to help separate patients with decreased EABV from those with SIADH.\textsuperscript{85,86} The diagnostic accuracy of these tests is limited, particularly in elderly patients who more commonly have hyponatremia

\[ {\text{FE}}_{{\text{Na}}} >30 \text{ mmol/l and fractional excretion (FE) of Na}^+ (\text{FE}_{{\text{Na}^+}}; \text{Equation } 1) >0.5\% \text{ are thought to be in keeping with euvolemic and the diagnosis of SIADH. The } \text{U}_{{\text{Na}}} \text{ may be } <30 \text{ mmol/l, however, in some patients with SIADH if their salt intake is low, and } >30 \text{ mmol/l in elderly patients who may have decreased ability to conserve salt despite decreased EABV and in the steady state excrete the salt they eat.} \quad \text{87,88} \]  

The calculation of the FE\textsubscript{Na} is also affected by the glomerular filtration rate (e.g., for the same rate of Na\textsuperscript{+} excretion, FE\textsubscript{Na} will be twice as high in an individual whose glomerular filtration rate is reduced by 50% compared with another individual who has a normal glomerular filtration rate). A \text{U}_{{\text{Na}}} >30 \text{ mmol/l was observed in 30% of the patients with hyponatremia who were thought to have hypovolemia, FE\textsubscript{Na} was } <0.5\% \text{ in 40% of patients who were thought to have SIADH.}

\[ \text{FE}_{{\text{Na}}} = \left[ \frac{\text{U}_{{\text{Na}}} \times \text{P}_{{\text{Na}}} \times \text{P}_{{\text{Creatinine}}} \times \text{U}_{{\text{Creatinine}}} \times 100}{\left( \frac{\text{P}_{{\text{Na}}}}{\text{P}_{{\text{Creatinine}}}} \right)} \right] \]  

Reabsorption of urea and urate in the PCT is increased in response to decreased EABV. FE of urea (FE\textsubscript{Urea}) <50% was observed in 80% of patients who were thought to have hypovolemia, but also in 50% of patients who were thought to have SIADH. FE of urate (FE\textsubscript{Urate}) <10% was observed in only 60% of patients who were thought to have hypovolemia and also in 50% of patients who were thought to have SIADH.

A trial of EABV expansion with infusion of saline may be required to differentiate patients with SIADH from those with mildly contracted EABV. The occurrence of water diuresis is expected in patients with low EABV but not in patients with SIADH, who are also expected to rapidly excrete the salt load. Of note, a subset of patients (~20%) with SIADH may have diminished baroreceptors sensitivity, mimicking the effect of decreased EABV. EABV expansion in this subset of patients may activate these stretch baroreceptors, leading to inhibition of the release of AVP and the excretion of a dilute urine.\textsuperscript{89}

With discontinuation of thiazides and provision of salt, patients with thiazide-induced hyponatremia are expected to excrete a dilute urine, resulting in the correction of hyponatremia. Increasing salt intake may also help correct the hyponatremia in patients with SIADH, because the increase in the number of excreted effective osmoles increases the urine volume. These patients however, fail to excrete a dilute urine.

Hypouricemia and increased FE\textsubscript{Urate} in patients with SIADH are thought to be due increased renal clearance of urate because of EABV expansion due to water retention, an effect of V1 receptor activation by AVP and perhaps also an effect of chronic hyponatremia.\textsuperscript{90–94} Correction of hyponatremia in these patients with water restriction results in normalization of the FE\textsubscript{Urate}.

Debate continues about the existence and true prevalence of the syndrome of cerebral salt wasting.\textsuperscript{96–98} A high FE\textsubscript{Urate} was observed in patients who were thought to have cerebral salt wasting and in a subset of patients with renal salt wasting who did not have an intracranial lesion.\textsuperscript{99–103} The suggested pathophysiology in these patients is the release of a yet unidentified circulating factor that inhibits the reabsorption of Na\textsuperscript{+} and of urate in the PCT.

In few reported cases, the FE\textsubscript{Urate} remained elevated in patients who were though to have cerebral/renal salt wasting after correction of hyponatremia with infusion of saline that resulted in the excretion of dilute urine. Hence, it was suggested that the FE\textsubscript{Urate} after correction of hyponatremia may differentiate patients with SIADH from those with cerebral salt wasting/renal salt wasting. Because this difference becomes only apparent after the correction of hyponatremia, it has limited utility in helping clinicians to decide what is the correct diagnosis and what is the appropriate therapy.
Patients With HCMA

There are 2 major pathophysiological mechanisms for the development of HCMA: the direct loss of NaHCO₃ (i.e., Na⁺ and HCO₃⁻ are both lost via the same route) and the indirect loss of NaHCO₃ (i.e., Na⁺ and HCO₃⁻ are lost via 2 different routes).

A direct loss of NaHCO₃ may occur via the gastrointestinal tract. Because the capacity of the Cl⁻/HCO₃⁻ anion exchanger in the colon normally exceeds that of the Na⁺/H⁺ exchanger, NaHCO₃ may be lost in stools if there is a large increase in the delivery of NaCl to the colon in a patient with diarrhea. If there is also increased production of organic acids in the colon in these patients, HCO₃⁻ may be titrated by H⁺ of these acids, and Na⁺ (or K⁺) ions are lost in the stool with the anions of these organic acids. In either case, there is a loss of NaHCO₃.

A direct loss of NaHCO₃ through the urine occurs in patients in the early phase of a disease process that causes proximal renal tubular acidosis (pRTA).

An indirect loss of NaHCO₃ could be the result of 2 different groups of disorders. In the first group, there is overproduction of an acid and a high rate of excretion of its anion (e.g., hippurate ketoacid anions, D-lactate) with NH₄⁺ in the urine.

![Diagram of Hyperchloremic Metabolic Acidosis]

Figure 3. Urine data in the clinical diagnosis of the patients with hyperchloremic metabolic acidosis (HCMA). The concentration of ammonium (NH₄⁺) in the urine can be estimated by dividing the urine (U) osmolal gap by 2, the rate of excretion of NH₄⁺ can be calculated by multiplying the UNH₄/Ucreatinine by the estimated rate of excretion of creatinine in the patient. A rate of excretion of NH₄⁺ >50 mmol/d suggests that renal tubular acidosis (RTA) is not the cause of the HCMA. In patients with HCMA and a high rate of excretion of NH₄⁺, one can determine whether an anion other than chloride is being excreted with NH₄⁺ in the urine by comparing the concentrations of sodium and potassium in the urine (U Na⁺ + U K⁺) versus that of chloride (U Cl⁻). The urine pH may provide a clue to suggest the pathophysiology causing a low rate of excretion of NH₄⁺. A urine pH >6 suggests a defect in bicarbonate (HCO₃⁻) reabsorption in the proximal convoluted tubule (early phase of proximal RTA [pRTA]) or a defect in H⁺ secretion in the distal nephron. Urine citrate excretion is not low in the former group. The pathophysiology causing decreased net H⁺ secretion in the distal nephron can be determined by measuring the PCO₂ in alkaline urine (U CO₂). ATPase, adenosine 5'-triphosphatase; dRTA, distal RTA; GFR, glomerular filtration rate; PCT, proximal convoluted tubule; SAO, Southeast Asian ovalocytosis.
The initial step in the differential diagnosis in patients with HCMA is to assess the rate of NH$_4^+$ excretion, which is expected to be high in patients with gastrointestinal loss of HCO$_3^-$ and in those with overproduction of an acid with a high rate of excretion of its anion in the urine, and to be low in patients with distal RTA (Figure 3). Of note, while pRTA in its initial phase is a NaHCO$_3$ wasting disease, the metabolic acidemia in the chronic steady state of this disorder seems to be maintained by a low rate of NH$_4^+$ excretion. A study in patients with isolated autosomal-dominant pRTA showed that the rate of NH$_4^+$ excretion was “normal” in the steady state (in fact, low considering the presence of chronic acidemia), and failed to rise appropriately in response to ammonium chloride (NH$_4$Cl) loading. It is postulated that the lesion that impairs the reabsorption of HCO$_3^-$ in the PCT results in an alkaline intracellular pH, which inhibits the activity of some key enzymes in glutamine metabolism.

**Assess the Rate of NH$_4^+$ Excretion**

The urine pH is not a reliable indicator for the rate of NH$_4^+$ excretion. In acute acidosis, distal H$^+$ secretion is stimulated, but there is a lag period before NH$_4^+$ production is increased; the urine pH is low, but there is only a modest increase in NH$_4^+$ excretion. In chronic acidosis, NH$_4^+$ production and the transfer of NH$_3$ into the lumen of the collecting duct are increased; a high rate of NH$_4^+$ excretion is achieved while the urine pH rises to ~6 as more NH$_3$ becomes available to titrate the H$^+$ ions.

Because a direct assay for urine NH$_4^+$ is not often available in clinical settings, indirect tests are used to estimate the NH$_4^+$ excretion rate in patients with HCMA. Although these tests provide only semiquantitative estimates, this is adequate for clinical use because the information needed is whether the rate of NH$_4^+$ excretion is low enough that a defect in renal NH$_4^+$ excretion is the cause of the metabolic acidosis or whether it is sufficiently high that another cause of the HCMA should be considered. Normal individuals consuming a typical Western diet excrete 30 to 40 mmol of NH$_4^+$ per day, whereas NH$_4^+$ excretion rose to >200 mmol/d in normal individuals who were given an acid load of NH$_4$Cl for several days.

**The Urine Anion Gap**

The urine anion gap (U$_{\text{Anion gap}}$), calculated as $(U_{Na} + U_K - U_{Cl})$, has been used to assess the rate of NH$_4^+$ excretion in patients with HCMA. The rationale behind this calculation is that if the rate of NH$_4^+$ excretion is high and NH$_3^+$ is excreted with Cl$^-$ (as is the case in patients with gastrointestinal loss of HCO$_3^-$), U$_{Cl}$ will exceed $(U_{Na} + U_K)$ (a negative value of the U$_{\text{Anion gap}}$). In contrast, if there is a defect in NH$_4^+$ excretion, $(U_{Na} + U_K)$ will exceed U$_{Cl}$ (a positive value of the U$_{\text{Anion gap}}$). There are 2 issues with using the U$_{\text{Anion gap}}$ that should be noted.

First, the equation that describes the relationship between the rate of NH$_4^+$ excretion and the U$_{\text{Anion gap}}$, which was based on measurements from 24-hour urine collections, had a constant of 82 (Equation 2).

$$\text{NH}_4^+\text{excretion} = -0.8(\text{urine anion gap}) + 82 \quad (2)$$

This constant represents the difference between the rates of excretion of other unmeasured anions and other unmeasured cations in the urine in individuals described as consuming a “normal” diet. Therefore, if U$_{Cl}$ exceeds $(U_{Na} + U_K)$, one assumes that NH$_4^+$ excretion is >82 mEq/d, and hence, RTA is not the cause of the metabolic acidosis. The validity of this assumption is rather questionable, because the rate of excretion of unmeasured anions in the urine may vary considerably depending on dietary intake.

The use of the U$_{\text{Anion gap}}$ in spot urine samples was examined in a study of patients with RTA, patients with diarrhea, and normal individuals given an acid load of NH$_4$Cl for 3 days. All patients with RTA had a positive value for the U$_{\text{Anion gap}}$, and patients with diarrhea and normal individuals given NH$_4$Cl had a negative value. The correlation between the value of the U$_{\text{Anion gap}}$ and the concentration of NH$_4^+$ in the urine ($U_{NH4}$), however, was only 0.72. NH$_4^+$ excretion rates were not reported, but based on the data provided on $U_{NH4}$ in a Figure in the paper, NH$_4^+$ excretion seemed to be lower than expected in some of the participants given NH$_4$Cl and some patients with diarrhea. Three of the 7 normal participants given NH$_4$Cl had $U_{NH4} < 30\text{ mmol/l}$. Four of the 8 patients with diarrhea had $U_{NH4}$ approximately or <30 mmol/l, and the $U_{NH4}$ in 2 of these patients was in the range observed in the patients with RTA.

The second issue is that the U$_{\text{Anion gap}}$ detects NH$_4^+$ only if it is excreted with Cl$^-$. Hence, if NH$_3^+$ is excreted with another anion (e.g., hippurate, β-hydroxy butyrate, D-lactate), the U$_{\text{Anion gap}}$ will fail to detect a high rate of NH$_4^+$ excretion, and these patients may be misdiagnosed as RTA.

**The Urine Osmolal Gap**

The urine osmolal gap (U$_{\text{Osmolal gap}}$) may provide a better indirect test to assess the rate of NH$_4^+$ excretion in patients with HCMA. The U$_{\text{Osmolal gap}}$ is calculated as the difference between the measured U$_{\text{Osm}}$ and the U$_{\text{Osm}}$ calculated from $2(U_{Na} + U_K) + U_{\text{Urea}} + U_{\text{Glucose}}$ (if hyperglycemia is present). Multiplying $(U_{Na} + U_K)$ by 2, accounts for their accompanying anions. This overestimates the actual number of
osmoles in the urine because some of these anions (e.g., SO₄²⁻, citrate²⁻, and perhaps some other organic anions) are not monovalent. On the other hand, the calculation of the U_{Osm} underestimates the actual number of urine osmoles because it does not include calcium and magnesium and their accompanying anions.

Meregalli et al. in a study in normal individuals and Raphael and Xi in a study in kidney transplant recipients, a small subset of whom had HCMA, noted poor correlation between the value of the U_{Osm}al gap and the concentration of NH₄⁺ in the urine. We emphasize that the purpose of the calculation of the U_{Osm}al gap is not to determine the actual concentration of NH₄⁺ in the urine but rather to assess if the rate of excretion of NH₄⁺ in a patient with HCMA is sufficiently high that a cause for the HCMA other than RTA should be considered.

The U_{Osm}al gap detects NH₄⁺ in the urine regardless of its accompanying anion. The U_{Osm}al gap is unreliable to assess the rate of NH₄⁺ excretion if other osmoles (e.g., ethanol, methanol, ethylene glycol, mannitol) are present in the urine.

The concentration of NH₄⁺ in the urine can be estimated by dividing the U_{Osm}al gap by 2, and the rate of NH₄⁺ excretion can be calculated by multiplying the U_{NH₄}/U_{Creatinine} by the estimated rate of excretion of creatinine in the patient. An estimated rate of NH₄⁺ excretion >50 mmol/d suggests that RTA is not likely to be the cause of the HCMA.

**Urinary Tests to Determine the Cause of Low NH₄⁺ Excretion**

The low rate of NH₄⁺ excretion could be due to decreased availability of NH₃ in the lumen of the collecting duct, because of decreased NH₄⁺ production, a defect in NH₄⁺ transfer to the medullary interstitium, or NH₃ transfer to the lumen of the collecting duct via the nonerythroid Rhesus glycoproteins Rhbg and Rhcg, and/or decreased net rate of H⁺ secretion in the distal nephron.

A low rate of NH₄⁺ production may be due to alkalization of PCT cells because of hyperkalemia or a genetic or an acquired disorder that compromises proximal H⁺ secretion or the exit of HCO₃⁻ from PCT cells, also causing reduced capacity to reabsorb HCO₃⁻ (i.e., pRTA). pRTA typically occurs in patients with Fanconi syndrome, in which other Na⁺-linked transport functions of PCT are affected, leading to renal glucosuria, aminoaciduria, citaturia, and increased fractional excretion rates of phosphate and urate. The common causes of Fanconi syndrome are paraproteinemias in adults and cystinosis in children.

A low net rate of H⁺ secretion in the distal nephron could be due to an H⁺—adenosine 5′-triphosphatase defect (e.g., autoimmune and hypergammaglobulinemic disorders, including Sjögren syndrome), back-leak of H⁺ (e.g., due to drugs such as amphotericin B), or a disorder associated with the distal secretion of HCO₃⁻ (e.g., in some patients with Southeast Asian ovalocytosis who have a second mutation in the Cl⁻/HCO₃⁻ anion exchanger causing it to be mis-targeted to the luminal membrane of β-intercalated cells).

The following urinary tests may help to determine the basis of the low rate of NH₄⁺ excretion (Figure 3):

The Urine pH. The urine pH should be measured with a pH meter in a freshly collected urine sample, or in a urine sample collected under mineral oil, to minimize diffusion of CO₂, if there will be a delay in performing the measurement. The basis for the low rate of NH₄⁺ excretion may be deduced from the urine pH. A urine pH of ~5 suggests a defect causing a low rate of NH₄⁺ production or impairing the accumulation of NH₄⁺ in the medullary interstitium/transfer of NH₄⁺ to the lumen of the MCD. A urine pH >6 suggests a defect in HCO₃⁻ reabsorption in the PCT (early phase of pRTA) or a defect in H⁺ secretion in the distal nephron.

The Rate of Citrate Excretion. The usual rate of citrate excretion is ~2 mmol/d. The rate of citrate excretion provides a window into the pH in PCT cells. Patients with metabolic acidosis have hypocitraturia, partly because of the effect of the lower pH in PCT cells to stimulate the reabsorption of citrate. Citrate excretion however, is not low in patients with pRTA because of decreased citrate reabsorption as a result of an alkaline PCT cell pH and/or as a component of Fanconi syndrome. An alkaline urine pH in this setting suggests the diagnosis of pRTA in the initial phase. Citrate excretion was reported to be also not low in a patient with carbonic anhydrase II deficiency. Different from inhibition of luminal carbonic anhydrase IV by acetazolamide, which is associated with marked hypocitraturia, deficiency of the cytoplasmic carbonic anhydrase II leads to an alkaline pH in PCT cells, which decreases the metabolism of citrate in PCT cells and subsequently decreases citrate reabsorption. Carbonic anhydrase II deficiency involves also the distal nephron causing decreased distal H⁺ secretion.

The Pco₂ in Alkaline Urine. The urinary Pco₂ is used to assess H⁺ secretion in the distal nephron. The patient is given a load of NaHCO₃ to increase the filtered load of HCO₃⁻ and its delivery to the distal nephron. Secretion of H⁺ by the MCD leads to the formation of carbonic acid (H₂CO₃). Because there is no
luminal carbonic anhydrase, H$_2$CO$_3$ is dehydrated slowly to CO$_2$ + H$_2$O. Urinary Pco$_2$ close to 70 mm Hg suggests a normal rate of net H$^+$ secretion in the distal nephron.

Despite a defect in distal H$^+$ secretion, the urinary Pco$_2$ is high in patients with a lesion that leads to H$^+$ back-leak. This is because as more HCO$_3^-$ is delivered distally, it traps H$^+$ and prevents its back-leak. The urinary Pco$_2$ is also high in patients with disorders that cause HCO$_3^-$ secretion in the distal nephron (e.g., some patients with SOA). This is because secretion of HCO$_3^-$ into the lumen of the distal nephron during HCO$_3^-$ loading raises the luminal fluid pH, causing H$^+$ to be released from monovalent phosphate (H$_3$PO$_4$), these H$^+$ react with luminal HCO$_3^-$ and form H$_2$CO$_3$.

FE of HCO$_3^-$ The FE of HCO$_3^-$ is used to assess H$^+$ secretion by the PCT. NaHCO$_3$ is given to raise the plasma HCO$_3$ to the normal range. If there is a defect in H$^+$ secretion in the PCT, the filtered load of HCO$_3^-$ will exceed the capacity for its reabsorption, and HCO$_3^-$ will be spilled in the urine; hence the urine pH becomes alkaline with values >7, and the FE of HCO$_3^-$ exceeds 15%.

This test is usually not needed. These patients will be recognized clinically by failure to correct their metabolic acidemia despite large doses of NaHCO$_3$.
64. Zimmerhackl BL, Robertson CR, Jamison RL. The medullary microcirculation. *Kidney Int*. 1987;31:641–647.

65. Zerbe RL, Robertson GL. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. *N Engl J Med*. 1981;305:1539–1546.

66. Milles JJ, Spruce B, Baylis PH. A comparison of diagnostic methods to differentiate diabetes insipidus from primary polyuria: a review of 21 patients. *Acta Endocrinol (Copenh)*. 1983;104:410–416.

67. Fenske W, Quinkler M, Lorenz D, et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome—revisiting the direct and indirect water deprivation tests. *J Clin Endocrinol Metab*. 2011;96:1506–1515.

68. Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. *Obstet Gynecol Surv*. 1998;53:450–455.

69. Rose BD. New approach to disturbances in the plasma sodium concentration. *Am J Med*. 1986;81:1033–1040.

70. Mallie JP, Bichet DG, Halperin ML. Effective water clearance and tonicity balance: the excretion of water revisited. *Clin Invest Med*. 1997;20:16–24.

71. Carlotti AP, Bohn D, Mallie JP, Halperin ML. Tonicity balance, and not electrolyte-free water calculations, more accurately guides therapy for acute changes in natriemia. *Intensive Care Med*. 2001;27:921–924.

72. Mallie JP. Hyponatraemia and tonicity balance. *Nephrol Dial Transplant*. 1999;14:1332–1333.

73. Kamel KS, Magner PO, Ethier JH, Halperin ML. Urine electrolytes in the assessment of extracellular fluid volume contraction. *Am J Nephrol*. 1989;9:344–347.

74. Adrogue HJ, Madias NE. Hyponatremia. *N Engl J Med*. 2000;342:1581–1589.

75. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. *N Engl J Med*. 2007;356:2064–2072.

76. Goldsmith SR, Francis GS, Cowley AW, Cohn JN. Response of vasopressin and norepinephrine to lower body negative pressure in humans. *Am J Physiol*. 1982;243:H970–H973.

77. Robertson GL. Vasopressin. In: Seldin DW, Giebisch G, eds. *The Kidney: Physiology and Pathophysiology*. Philadelphia, PA: Lippincott; 2000:1132–1152.

78. Thaler SM, Teitelbaum I, Berl T. “Beer potomania” in non-beer drinkers: effect of low dietary solute intake. *Am J Kidney Dis*. 1998;31:1028–1031.

79. Filippone EJ, Ruzieh M, Foy A. Thiazide-associated hyponatremia: clinical manifestations and pathophysiology. *Am J Kidney Dis*. 2020;75:256–264.

80. Kamel KS, Halperin ML. The importance of distal delivery of filtrate and residual water permeability in the pathophysiology of hyponatremia. *Nephrol Dial Transplant*. 2012;27:872–875.

81. Ware JS, Wain LV, Channavajjhala SK, et al. Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia. *J Clin Invest*. 2017;127:3367–3374.

82. Oh MS, Carroll HJ, Roy A. Chronic hyponatremia in the absence of ADH: possible role of decreased delivery of filtrate. *J Am Soc Nephrol*. 1997;8:108A.

83. Chung HM, Kluge R, Schrier RW, Anderson RJ. Clinical assessment of extracellular fluid volume in hyponatremia. *Am J Med*. 1987;83:905–908.

84. Musch W, Thimpong J, Vandervelde D, et al. Combined fractional excretion of sodium and urea better predicts response to saline in hyponatremia than do usual clinical and biochemical parameters. *Am J Med*. 1995;99:348–355.

85. Decaux G, Musch W. Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. *Clin J Am Soc Nephrol*. 2008;3:1175–1184.

86. Musch W, Decaux G. Utility and limitations of biochemical parameters in the evaluation of hyponatremia in the elderly. *Int Urol Nephrol*. 2001;32:475–493.

87. Beck LH. Changes in renal function with aging. *Clin Geriatr Med*. 1998;14:199–209.

88. Mallie JP, Chevet D, Jeandel C. Defective post-diuretic antinatriuresis in aging kidney: a possible explanation for thiazide-induced hyponatremia in the elderly. *Geriatr Nephrol Urol*. 1995;4:153–160.

89. Fenske WK, Christ-Crain M, Horning A, et al. A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis. *J Am Soc Nephrol*. 2014;25:2376–2383.

90. Beck LH. Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone. *N Engl J Med*. 1979;301:528–530.

91. Dorhout Mees EJ, Blom van Assendelft P, Nieuwenhuis MG. Elevation of uric acid clearance caused by inappropriate antidiuretic hormone secretion. *Acta Med Scand*. 1971;189:69–72.

92. Sonnenblick M, Rosin A. Increased uric acid clearance in the syndrome of inappropriate secretion of antidiuretic hormone. *Isr J Med Sci*. 1988;24:20–23.

93. Decaux G, Namias B, Gulbis B, Soupart A. Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. *J Am Soc Nephrol*. 1996;7:805–810.

94. Decaux G, Prospert F, Soupart A, Musch W. Evidence that chronicity of hyponatremia contributes to the high urate clearance observed in the syndrome of inappropriate antidiuretic hormone secretion. *Am J Kidney Dis*. 2000;36:745–751.

95. Weinberger A, Santo M, Solomon F, et al. Abnormality in renal urate excretion rates in hyponatremic conditions and biochemical parameters in the evaluation of hyponatremia in the elderly. *Clin J Am Soc Nephrol*. 2018;13:493–499.

96. Oh MS, Carroll HJ. Cerebral salt-wasting syndrome. We need better proof of its existence. *Nephron*. 1999;82:110–114.

97. Singh S, Bohn D, Carlotti AP, Cusimano M, et al. Cerebral salt wasting: truths, fallacies, theories, and challenges. *Crit Care Med*. 2002;30:2575–2579.

98. Verbalis JG. The curious story of cerebral salt wasting: fact or fiction? *Clin J Am Soc Nephrol*. 2020;15:1666–1668.

99. Maesaka JK, Imbriano LJ, Miyawaki N. Determining fractional urate excretion rates in hyponatremic conditions and improved methods to distinguish cerebral/renal salt wasting from the syndrome of inappropriate secretion of antidiuretic hormone. *Front Med (Lausanne)*. 2018;5:319.

100. Imbriano LJ, Mattana J, Drakakis J, Maesaka JK. Identifying different causes of hyponatremia with fractional excretion of uric acid. *Am J Med. Sci*. 2016;352:385–390.
101. Maesaka JK, Imbriano LJ, Miyawaki N. High prevalence of renal salt wasting without cerebral disease as cause of hyponatremia in general medical wards. Am J Med Sci. 2018;356:15–22.

102. Bitew S, Imbriano L, Miyawaki N, et al. More on renal salt wasting without cerebral disease: response to saline infusion. Clin J Am Soc Nephrol. 2009;4:309–315.

103. Maesaka JK, Imbriano LJ, Miyawaki N. Evolution and evolving resolution of controversy over existence and prevalence of cerebral/renal salt wasting. Curr Opin Nephrol Hypertens. 2020;29:213–220.

104. Carlisle EJ, Donnelly SM, Vasuvattakul S, et al. Glue-sniffing and distal renal tubular acidosis: sticking to the facts. J Am Soc Nephrol. 1991;1:1019–1027.

105. Brenes LG, Sanchez MI. Impaired urinary ammonium excretion in patients with isolated proximal renal tubular acidosis. J Am Soc Nephrol. 1993;4:1073–1078.

106. Halperin ML, Kamel KS, Ethier JH, Magner PO. What is the underlying defect in patients with isolated, proximal renal tubular acidosis? Am J Nephrol. 1989;9:265–268.

107. Halperin ML, Kamel KS, Briceno LF, Sanchez MI, et al. A new classification for renal defects in net acid excretion. Am J Kidney Dis. 1997;29:136–146.

108. Richardson RM, Halperin ML. The urine pH: a potentially misleading diagnostic test in patients with hyperchloremic metabolic acidosis. Am J Kidney Dis. 1987;10:140–143.

109. Carlisle EJ, Donnelly SM, Halperin ML. Renal tubular acidosis (RTA): recognize the ammonium defect and pH or get the urine pH. Pediatr Nephrol. 1991;5:242–248.

110. Simpson DP. Control of hydrogen ion homeostasis and renal acidosis. Medicine (Baltimore). 1971;50:503–541.

111. Madison LL, Seldin DW. Ammonia excretion and renal enzymatic adaptation in human subjects, as disclosed by administration of precursor amino acids. J Clin Invest. 1958;37:1615–1627.

112. Goldstein MB, Bear R, Richardson RM, et al. The urine anion gap: a clinically useful index of ammonium excretion. Am J Med Sci. 1986;292:198–202.

113. Oh M, Carroll HJ. Value and determinants of urine anion gap. Nephron. 2002;90:252–255.

114. Battle DC, Hizon M, Cohen E, et al. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med. 1988;318:594–599.

115. Dyck RF, Asthana S, Kalra J, et al. A modification of the urine osmolar gap: an improved method for estimating urine ammonium. Am J Nephrol. 1990;10:359–362.

116. Halperin ML, Margolis BL, Robinson LA, et al. The urine osmolar gap: a clue to estimate urine ammonium in “hybrid” types of metabolic acidosis. Clin Invest Med. 1988;11:196–202.

117. Kamel KS, Halperin ML. An improved approach to the patient with metabolic acidosis: a need for four amendments. J Nephrol. 2006;19(suppl 9):S76–S85.

118. Halperin ML, Kamel KS. Some observations on the clinical approach to metabolic acidosis. J Am Soc Nephrol. 2010;21:894–897.

119. Meregalli P, Luty C, Oetliker OH, Bianchetti MG. Modified urine osmolar gap: an accurate method for estimating the urinary ammonium concentration? Nephron. 1995;69:98–101.

120. Raphael KL, Ix JH. Correlation of urine ammonium and urine osmolar gap in kidney transplant recipients. Clin J Am Soc Nephrol. 2018;13:638–640.

121. Weiner ID, Verlander JW. Renal ammonia metabolism and transport. Compr Physiol. 2013;3:201–220.

122. Kurtz I. Renal tubular acidosis: H(+)/base and ammonia transport abnormalities and clinical syndromes. Adv Chronic Kidney Dis. 2018;25:334–350.

123. Haque SK, Ariceta G, Battle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transplant. 2012;27:4273–4287.

124. Simpson DP. Citrate excretion: a window on renal metabolism. Am J Physiol. 1983;244:F223–F234.

125. Hamm LL. Renal handling of citrate. Kidney Int. 1990;38:728–735.

126. Hering-Smith KS, Hamm LL. Acidosis and citrate: provocative interactions. Ann Transl Med. 2018;6:374.

127. Dedmon RE, Wrong O. The excretion of organic anion in renal tubular acidosis with particular reference to citrate. Clin Sci. 1962;22:19–32.

128. Wrong O, Davies HE. The excretion of acid in renal disease. Q J Med. 1959;28:259–313.

129. Norman ME, Feldman NI, Cohn RM, et al. Urinary citrate excretion in the diagnosis of distal renal tubular acidosis. J Pediatr. 1978;92:394–400.

130. Nagai R, Kooh SW, Balfe JW, et al. Renal tubular acidosis and osteoporosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification. Pediatr Nephrol. 1997;11:633–636.

131. Ohlsson A, Cumming WA, Paul A, Sly WS. Carbonic anhydrase II deficiency syndrome: recessive osteoporosis with renal tubular acidosis and cerebral calcification. Pediatrics. 1986;77:371–381.

132. Halperin ML, Goldstein MB, Haig A, et al. Studies on the pathogenesis of type I (distal) renal tubular acidosis as revealed by the urinary PCO2 tensions. J Clin Invest. 1974;53:669–677.

133. DuBose TD Jr. Hydrogen ion secretion by the collecting duct as a determinant of the urine to blood PCO2 gradient in alkaline urine. J Clin Invest. 1982;69:145–156.

134. DuBose TD Jr, Cafisich CR. Validation of the difference in urine and blood carbon dioxide tension during bicarbonate loading as an index of distal neprhen acidification in experimental models of distal renal tubular acidosis. J Clin Invest. 1985;75:1116–1123.

135. Roscoe JM, Goldstein MB, Halperin ML, et al. Effect of amphotericin B on urine acidification in rats: implications for the pathogenesis of distal renal tubular acidosis. J Lab Clin Med. 1977;89:463–470.

136. Kaitwatcharachai C, Vasuvattakul S, Yenchitsommanus P, et al. Distal renal tubular acidosis and high urine carbon dioxide tension in a patient with southeast Asian ovalocytosis. Am J Kidney Dis. 1999;33:1147–1152.

137. Jarolim P, Shayakul C, Prabakaran D, et al. Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl⁻/HCO₃⁻ exchanger. J Biol Chem. 1998;273:6380–6388.

138. Elkington JR. The kidney and hydrogen ion metabolism. Bibl Paediatr. 1960;74:99–123.